ALL
51
7
VRSK
40
-2
SRE
52
2
PGR
70
-3
DGX
46
-2
AEE
41
-4
EW
38
-4
ILMN
38
2
BWA
50
9
HCP
78
-2
MSFT
60
5
VTR
78
2
MMC
48
-3
BXP
47
-3
ETN
87
4
MPC
52
10
WEC
29
-5
SJM
33
9
HOG
33
6
UA
33
3
ALL
51
7
VRSK
40
-2
SRE
52
2
PGR
70
-3
DGX
46
-2
AEE
41
-4
EW
38
-4
ILMN
38
2
BWA
50
9
HCP
78
-2
MSFT
60
5
VTR
78
2
MMC
48
-3
BXP
47
-3
ETN
87
4
MPC
52
10
WEC
29
-5
SJM
33
9
HOG
33
6
UA
33
3
Financhill
Back

Deciphera Pharmaceuticals 10K Form

Sell
25

DCPH
Deciphera Pharmaceuticals

Last Price:
14.66
Seasonality Move:
6.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DCPH News And Ratings

See the #1 stock for the next 7 days that we like better than DCPH

DCPH Financial Statistics

Sales & Book Value

Annual Sales: $163.36M
Cash Flow: $-28.87M
Price / Cash Flow: 0
Annual Sales: $4.36
Price / Book: 3.37

Profitability

EPS (TTM): -2.29000
Net Income (TTM): $-194.94M
Gross Margin: $159.62M
Return on Equity: -50.8%
Return on Assets: -39.24%

Deciphera Pharmaceuticals Earnings Forecast

Key Deciphera Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for DCPH is 97.72%.
  • The Selling, General & Administrative Expenses for DCPH have been equal to 83.53% of Gross Profit Margin.
  • The Research & Development expenses have been 143.32% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of DCPH is -119.34% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 3 years.

Deciphera Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DCPH
CUSIP: 24344T
Website: deciphera.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.8
Quick Ratio: 3.37

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DCPH Technical Analysis vs Fundamental Analysis

Sell
25
Deciphera Pharmaceuticals (DCPH) is a Sell

Is Deciphera Pharmaceuticals a Buy or a Sell?